January 6, 2017 / 12:08 PM / 7 months ago

BRIEF-Acceleron outlines corporate goals and priorities for 2017

Jan 6 (Reuters) - Acceleron Pharma Inc

* Acceleron outlines corporate goals and priorities for 2017

* Plan to initiate new luspatercept phase 2 clinical trials in distinct patient segments in MDS and Beta-Thalassemia

* Plan to initiate first phase 2 trial in Myelofibrosis

* Acceleron expects to present topline results from phase 2 dart study in second half of 2017 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below